A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show.

A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.

Results from a phase II randomised trial have shown that a combination of immunotherapy and a targeted therapy could extend time between treatments for some women with recurrent ovarian cancer.

Advanced radiotherapy technology can safely deliver curative treatment for prostate cancer patients in as few as five sessions, with only minimal side effects, according to new research from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows.

A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.

Men with particularly aggressive prostate cancers can be treated more effectively by combining an existing targeted medicine, abiraterone, with a new experimental drug to block two of cancer’s growth signals at once, a major new trial has shown.

To accelerate research and improve patient outcomes, the world’s first centre for recurrent head and neck cancer has been launched at The Royal Marsden NHS Foundation Trust thanks to Royal Marsden Cancer Charity funding. 

An artificial intelligence (AI) that reconstructs MRI images of moving tumours can do so in seconds, offering a significant improvement on current methods to optimise radiotherapy treatment in the clinic.

A new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease.